RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability

Nadal E.Horinouchi H.JIN-YUAN SHIHNakagawa K.Reck M.Garon E.B.Wei Y.-F.Kollmeier J.Frimodt-Moller B.Barrett E.Lipkovich O.Visseren-Grul C.Novello S.2022-06-272022-06-2720220114-5916https://www.scopus.com/inward/record.uri?eid=2-s2.0-85121456404&doi=10.1007%2fs40264-021-01127-2&partnerID=40&md5=76b47e3dc1a2850142f91402a226ede8https://scholars.lib.ntu.edu.tw/handle/123456789/613368RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageabilityjournal article10.1007/s40264-021-01127-2349284842-s2.0-85121456404